Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation

International Journal of Pharmaceutics

Volumn 471, Issue 1-2, 2014, Pages 430-438

  Gangadhar, Katkam N ^a   Adhikari, Kajiram ^a   Srichana, Teerapol ^a,b  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Aerosol; Amphotericin B; SDS AmB; Toxicities; Zeta potential

Indexed keywords

AMPHOTERICIN B; DEOXYCHOLATE SODIUM; DRUG CARRIER; SODIUM DEOXYCHOLATE SULFATE; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; DEOXYCHOLIC ACID; LIPID;

ARTICLE; CANDIDA ALBICANS; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIMIT OF DETECTION; LUNG ALVEOLUS MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; CELL LINE; CELL SURVIVAL; CHEMISTRY; CRYPTOCOCCUS NEOFORMANS; DRUG EFFECTS; ERYTHROCYTE; GROWTH, DEVELOPMENT AND AGING; SOLUBILITY; SURFACE PROPERTY; SYNTHESIS; TOXICITY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CELL LINE; CELL SURVIVAL; CRYPTOCOCCUS NEOFORMANS; DEOXYCHOLIC ACID; DRUG CARRIERS; ERYTHROCYTES; HUMANS; LIPIDS; MACROPHAGES, ALVEOLAR; PARTICLE SIZE; SOLUBILITY; SURFACE PROPERTIES;

EID: 84903219375     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.05.066     Document Type: Article

References (57)

1. J.P. Adler-Moore, and R.T. Proffitt Amphotericin B lipid preparations: what are the differences? Clin. Microbiol. Infect. 14 2008 25 36 (Pubitemid 351593914)
2. AHFS Drug Information 2009 American Society of Health-System Pharmacists Inc. 7272 Wisconsin Avenue, Bethesda, MD 20814, USA 542 554
3. A.I. Aller, E. Martin-Mazuelos, M.J. Gutierrez, S. Bernal, M. Chavez, and F.J. Recio Comparison of the E-test and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents J. Antimicrob. Chemother. 46 2000 997 1000 (Pubitemid 32000612)
4. L.K. Archibald, M.J. Tuohy, D.A. Wilson, O. Nwanyanwu, P.N. Kazembe, S. Tansuphasawadikul, B. Eampokalap, A. Chaovavanich, L.B. Reller, W.R. Jarvis, G.S. Hall, and G.W. Procop Antifungal susceptibility of Cryptococcus neoformans Emerg. Infect. Dis. 10 2004 143 145
5. T.M. Arnold, E. Dotson, G.A. Sarosi, and C.A. Hage Traditional and emerging antifungal therapies Proc. Am. Thorac. Soc. 7 2010 222 228
6. M. Baginski, and J. Czub Amphotericin B and its new derivatives-mode of action Curr. Drug Metab. 10 2009 459 469
7. J. Barwicz, S. Christian, and I. Gruda Effects of the aggregation state of amphotericin B on its toxicity to mice Antimicrob. Agents Chemother. 36 1992 2310 2315
8. J.E. Bennett Antimicrobial agents Alfred G. Gilman, The Pharmacological Basis of Therapeutics 1996 McGraw Hill New York, USA 1175 1190
9. A.C. Burns, P.W. Sorensen, and T.R. Hoye Synthesis and olfactory activity of unnatural, sulfated 5β-bile acid derivatives in the sea lamprey (Petromyzon marinus) Steroids 76 2011 291 300
10. B. Chudzik, I.B. Tracz, G. Czernel, M.J. Fiolka, G. Borsuk, and M. Gagos Amphotericin B-copper (II) complex as a potential agent with higher antifungal activity against Candida albicans Eur. J. Pharm. Sci. 49 2013 850 857
11. R. Chuealee, P. Aramwit, K. Noipha, and T. Srichana Bioactivity and toxicity studies of amphotericin B incorporated in liquid crystals Eur. J. Pharm. Sci. 43 2011 308 317
12. C. Cifani, S. Costantino, M. Massi, and L. Berrino Commercially available lipid formulations of amphotericin B: are they bioequivalent and therapeutically equivalent? Acta Biomedica. 83 2012 154 163
13. B.E. Cohen Amphotericin B membrane action: role for two types of ion channels in eliciting cell survival and lethal effects J. Membr. Biol. 238 2010 1 20
14. S. Das, P.K. Suresh, and R. Desmukh Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery Nanomed-Nanotechnol. 6 2010 318 323
15. R. Espada, S. Valdespina, C. Alfonso, G. Rivas, M.P. Ballesteros, and J.J. Torrado Effect of aggregation state on the toxicity of different amphotericin B preparations Int. J. Pharm. 361 2008 64 69
16. M. Fauvel, C. Farrugia, N. Tsapis, C. Gueutin, O. Cabaret, C. Bories, S. Bretagne, and G. Barratt Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity Int. J. Pharm. 436 2012 106 110
17. R.M. Fielding Relationship of pharmacokinetically-calculated volumes of distribution to the physiologic distribution of liposomal drugs in tissues: implications for the characterization of liposomal formulations Pharm. Res. 18 2001 238 242 (Pubitemid 32592605)
18. D. Forster, C. Washington, and S.S. Davis Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes J. Pharm. Pharmacol. 40 1988 325 328
19. A. Gharib, Z. Faezizadeh, and A.H. Mohammad Prepartion and antifungal activity of spray-dried amphotericin B-loaded nanospheres DARU J. Pharm. Sci. 19 2011 351 355
20. L.S.S. Guo, R.M. Fielding, D.D. Lasic, R.L. Hamilton, and D. Mufson Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs Int. J. Pharm. 75 1991 45 54
21. W.G. Hocking, and D.W. Golde The pulmonary-alveolar macrophage N. Engl. J. Med. 301 1979 580 587
22. 2+ ions J. Lipid Res. 33 1992 617 626
23. A.F. Hofmann, and K.J. Mysels Bile salts as biological surfactants Colloids Surf. 30 1988 145 173
24. S. Honary, and F. Zahir Effect of zeta potential on the properties of nano-drug delivery systems - a review (part 1) Trop. J. Pharm. Res. 12 2013 255 264
25. Y. Huang, S. Chen, J. Cui, C. Gan, Z. Liu, Y. Wei, and H. Song Synthesis and cytotoxicity of A-homo-lactam derivatives of cholic acid and 7-deoxycholic acid Steroids 76 2011 690 694
26. 3-PLA copolymers: an in vivo evaluation in a murine model Mol. Pharm. 8 2011 204 212
27. S.H. Jung, D.H. Lim, S.H. Jung, J.E. Lee, K.S. Jeong, H. Seong, and B.C. Shin Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics Eur. J. Pharm. Sci. 37 2009 313 320
28. L. Kuiper, and E.J. Ruijgrok A review on the clinical use of inhaled amphotericin B J. Aerosol Med. Pulm. Drug Deliv. 22 2009 213 217
29. L. Lazar, M. Csavas, A. Borbas, G. Gyemant, and A. Liptak Synthesis of methyl 6-deoxy-4-O-(sodium sulfonato)-α-l-talopyranoside, its C-4 epimer and both isosteric [4-C-(potassium sulfonatomethyl)] derivatives ARKIVOC 7 2004 196 207 (Pubitemid 38773725)
30. P. Legrand, E.A. Romero, B.E. Cohen, and J. Bolard Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes Antimicrob. Agents Chemother. 36 1992 2518 2522
31. A. Lemke, A.F. Kiderlen, and O. Kayser Amphotericin B Appl. Microbiol. Biotechnol. 68 2005 151 162 (Pubitemid 41110936)
32. O. Lopez-Jodra, J.M. Torres-Rodriguez, R. Mendez-Vasquez, E. Ribas-Forcadell, Y. Morera-Lopez, T. Baro-Tomas, and C. Alia-Aponte In vitro susceptibility of Cryptococcus neoformans isolated to five antifungal drugs using a colorimetric system and the reference microbroth methods J. Antimicrob. Chemother. 45 2000 645 649 (Pubitemid 30255645)
33. M. Lozano-Chiu, V.L. Paetznick, M.A. Ghannoum, and J.H. Rex Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and national committee for clinical laboratory standards M27-A methodologies J. Clin. Microbiol. 36 1998 2817 2822 (Pubitemid 28429397)
34. H.C. Maltezou Drug resistance in visceral leishmaniasis J. Biomed. Biotechnol. 2010 1 8
35. G.L. Mandell, J.E. Bennett, and R. Dolin Principles and Practice of Infectious Diseases 5th ed. 2000 Churchill Livingstone Philadelphia 448
36. J. Mazerski, and E. Borowski Molecular dynamics of amphotericin B. II. Dimer in water Biophys. Chem. 57 1996 205 217
37. M.R. McGinnis, and G.M. Rinaldi Antifungal drugs: mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biological fluids V. Lorian, Antibiotics in Laboratory Medicine 1991 Lippincott Williams & Wilkins Baltimore, Maryland 21202, USA 198 257
38. W. Meersseman, K. Lagrou, J. Maertens, and E. Van Wijngaerden Invasive aspergillosis in the intensive care unit Clin. Infect. Dis. 45 2007 205 216 (Pubitemid 47044802)
39. R. Mehta, B.G. Lopez, R. Hopfer, K. Mills, and R.L. Juliano Liposomal AmB is toxic to fungal cells but not to mammalian cells Biochem. Biophys. Acta 770 1984 230 234 (Pubitemid 14165264)
40. K.K. Nishi, M. Antony, P.V. Mohanan, T.V. Anilkumar, P.M. Loiseau, and A. Jayakrishnan Amphotericin B-gum arabic conjugates: synthesis, toxicity, bioavailability and activities against Leishmania and fungi Pharm. Res. 24 2007 971 980 (Pubitemid 46675399)
41. N. Ozdemir, and S. Ordu Improvement of dissolution properties of furosemide by complexation with β-cyclodextrin Drug Dev. Ind. Pharm. 24 1998 19 25 (Pubitemid 28080834)
42. B.J. Park, B.A. Arthington-Skaggs, R.A. Hajjeh, N. Iqbal, M.A. Ciblak, W. Lee-Yang, M.D. Hairston, M. Phelan, B.D. Plikaytis, A.N. Sofair, L.H. Harrison, S.K. Fridkin, and D.W. Warnock Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome Antimicrob. Agents Chemother. 50 2006 1287 1292
43. U. Persson, G.R. Tennvall, S. Andersson, G. Tyden, and B. Wettermark Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses PharmacoEconomics 2 1992 500 508
44. V.K. Prajapati, K. Awasthi, S. Gautam, T.P. Yadav, M. Rai, O.N. Srivastava, and S. Sundar Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes J. Antimicrob. Chemother. 66 2011 874 879
45. B.J. Rijnders, J.J. Cornelissen, L. Slobbe, M.J. Becker, J.K. Doorduijn, W.C.J. Hop, E.J. Ruijgrok, B. Luwenberg, A. Vulto, P.J. Lugtenburg, and S. de Marie Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial Clin. Infect. Dis. 46 2008 1401 1408 (Pubitemid 351589940)
46. A. Saeed, and Z. Ashraf Sodium borohydride reduction of aromatic carboxylic acids via methyl esters J. Chem. Sci. 118 2006 419 423 (Pubitemid 44546275)
47. C. Salerno, S. Perez, E. Monte agudo, A. Carlucci, and C. Bregni Solubility of amphotericin B in water-lecithin-dispersions and lecithin-based submicron emulsions Pak. J. Pharm. Sci. 26 2013 189 193
48. 2) J. Phys. Chem. B 113 2009 5863 5870
49. T. Sawada, S. Fujii, H. Nakano, S. Ohtake, K. Kimata, and O. Habuchi Synthesis of sulfated phenyl 2-acetamido-2-deoxy-d-galactopyranosides. 4-O-Sulfated phenyl 2-acetamido-2-deoxy-β-d-galactopyranoside is a competitive acceptor that decreases sulfation of chondroitin sulfate by N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase Carbohyd. Res. 340 2005 1983 1996 (Pubitemid 41033063)
50. B.H. Segal Aspergillosis N. Engl. J. Med. 360 2009 1870 1884
51. W.J. Steinbach, P.R. Juvvadi, J.R. Fortwendel, and L.E. Rogg Newer combination antifungal therapies for invasive aspergillosis Med. Mycol. 49 2011 S77 S81
52. C.L. Terrell, and C.E. Hughes Antifungal agents used for deep-seated mycotic infections Mayo Clin. Proc. 67 1992 69 91
53. J.J. Torrado, R. Espada, M.P. Ballesteros, and S. Torrado-Santiago Amphotericin B formulations and drug targeting J. Pharm. Sci. 97 2008 2405 2425
54. US Pharmacopeial Convention USP29-NF24. Guideline No. 66: Antibiotics, Microbial Assays 2006 USP Rockville, MD
55. H. Van de Ven, C. Paulussen, P.B. Feijens, A. Matheeussen, P. Rombaut, P. Kayaert, G. Van den Mooter, W. Weyenberg, P. Cos, L. Maes, and A. Ludwig PLGA nanoparticles and nanosuspenions with amphotericin B: potent in vitro and in vivo alternatives to fungizone and ambisome J. Control. Release 161 2012 795 803
56. J. Van Eldere, L. Joosten, V. Verhaeghe, and I. Surmont Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test J. Clin. Microbiol. 34 1996 842 847
57. B.G. Yu, T. Okano, K. Kataoka, and G. Kwon Polymeric micelles for drug delivery: solubilization and haemolytic activity of amphotericin B J. Control. Release 53 1998 131 136 (Pubitemid 28218696)